Pregnant women, prescription, and fetal risk.
Since the historical scandal of thalidomide in the 1960s, practitioners and future mothers are fearful of drugs during pregnancy. In-uterine exposure to drugs can induce major malformation of the fetus or even intrauterine fetal death. Prescribing drugs to a pregnant woman requires particular attention, and it is necessary to consider both the maternal needs and the proven and potential fetal risks. In this chapter, we review the mechanisms for medication transfer from mother to fetus, fetal risk according to pregnancy timeline, and the main dangerous drugs during pregnancy. We also focus on three prescription debates, which are relevant for neurodevelopmental disorder, because they each point to a paradigmatic situation-diethylstilbestrol, which shows transgenerational adversary effects; valproate, which impacts neurodevelopment as a whole; and antidepressants for which the adverse impact on neurodevelopment is still controversial given the impact of depression itself. Finally, we consider the implications for practice and toxicologic research to promote risk prevention.
['Eléfant|Elisabeth|E|', 'Hanin|Cyril|C|', 'Cohen|David|D|']
D000928:Antidepressive Agents D005260:Female D005333:Fetus D006801:Humans D011247:Pregnancy D011248:Pregnancy Complications D037841:Pregnant Women D055656:Prescriptions
Prescription Fetal risk Pregnancy Teratogenicity